Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...

In Q2 2025, the global pharma sector experienced a decline in M&A activity, with deals worth $32.9 billion, down 11.6% from Q1. Deal volume fell 12.8% to 130. Oncology led with 51 deals. Discover key ...